Exploratory investigation on antibodies to GluN1 and cognitive dysfunction in patients with chronic autoimmune psychosis
Exploratory investigation on antibodies to GluN1 and cognitive dysfunction in patients with chronic autoimmune psychosis
复制标题
DOI：
10.1016/j.neulet.2020.135588
复制
发表时间：
2021-01-19
影响因子：
2.5
通讯作者：
Hishimoto, Akitoyo
中科院分区：
文献类型：
--
作者：
Abe, Kie;Chiba, Yuhei;Hishimoto, Akitoyo
简介：轻度认知功能障碍与许多精神疾病有关，并影响社会功能。虽然最近提出了自身免疫性精神病（AP）的临床标准，但尚未建立认知功能障碍严重程度和预后的生物标志物。我们在此调查3种类型的血清抗体和认知功能障碍的慢性精神病患者疑似AP。方法：我们包括31例疑似AP，并获得他们的临床特征的信息。在血清中评价了三种类型的自身抗体（抗N-甲基-D-天冬氨酸受体（抗NMDAR Ab）、抗GluN 1的N-末端（抗GluN 1-NT Ab）和抗甲状腺抗体）。认知功能采用韦氏成人智力量表-III进行评估。结果：血清抗GluN 1-NT抗体滴度与工作记忆的估计值有显著性差异，但与工作记忆的估计值无显著性差异（P> 0.05（B=-55.85，beta=-0.46，p= 0.01），而未观察到其他2种抗体与认知功能之间的相关性。目前的研究结果表明，血清抗GluN 1-NT抗体作为AP患者各种精神症状相关的认知功能障碍的严重程度和预后的生物标志物的潜力。抗GluN 1-NT抗体的病理学意义有待进一步研究证实。
Introduction: Mild cognitive dysfunction has been implicated in a number of psychiatric diseases and affects social functioning. Although clinical criteria were recently proposed for autoimmune psychosis (AP), biomarkers have not yet been established for the severity and prognosis of cognitive dysfunction. We herein investigated the relationships between 3 types of serum antibodies and cognitive dysfunction in chronic psychiatric patients suspected of AP.Methods: We included 31 patients suspected of AP and obtained information on their clinical characteristics. Three types of autoantibodies (the anti-N-methyl-D-aspartate receptor (anti-NMDAR Ab), anti-N-terminal of GluN1 (anti-GluN1-NT Ab), and anti-thyroid antibodies) were evaluated in serum. Cognitive function was assessed using Wechsler Adult Intelligence Scale-III. We examined the relationships between serum autoantibodies and cognitive dysfunction in patients using multiple regression models.Results: Serum titers of anti-GluN1-NT Ab significantly contributed to the estimated score of working memory (B= -55.85, beta= -0.46, p= 0.01), while no correlation was observed between the other 2 types of antibodies and cognitive function.Conclusions: The present results indicate the potential of serum anti-GluN1-NT Ab as a biomarker for the severity and prognosis of cognitive dysfunction underlying various psychiatric symptoms in patients with AP. The pathological significance of anti-GluN1-NT Ab needs to be verified in future studies.